AbbVie was founded in 2013 and is headquartered in North Chicago, US
Report incorrect company information
Key People/Management at AbbVie
Richard Gonzalez
Chairman of the Board and Chief Executive Officer
Carlos Alban
Executive Vice President, Commercial Operations
Timothy Richmond
Senior Vice President, Human Resources
Azita Saleki-Gerhardt
Senior Vice President, Operations
Karen Hale
Vice President, Chief Ethics and Compliance Officer
Wulff-Erik von Borcke
President, Pharmacyclics
Report incorrect company information
AbbVie Office Locations
AbbVie has offices in Singapore, Campoverde, Sligo, San Francisco and in 12 other locations
North Chicago, US (HQ)
1 Waukegan Rd
Cambridge, US
200 Sidney St
Barceloneta, PR
PR-2
Report incorrect company information
AbbVie Financials and Metrics
AbbVie Financials
AbbVie's revenue was reported to be $25.64 b in FY, 2016 which is a 12.2% increase from the previous period.
| USD | |
|---|---|
Revenue (Q1, 2018) | 7.9 b |
Gross profit (Q1, 2018) | 6 b |
Gross profit margin (Q1, 2018), % | 75.7% |
Net income (Q1, 2018) | 2.8 b |
EBIT (Q1, 2018) | 2.9 b |
Market capitalization (21-May-2018) | 168.6 b |
Closing share price (21-May-2018) | 106.2 |
Cash (31-Mar-2018) | 9 b |
EV | 159.9 b |
AbbVie's current market capitalization is $168.6 b.
- Source: SEC Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 18.8 b | 20 b | 22.9 b | 25.6 b |
Revenue growth, % | 6% | 15% | 12% | |
Cost of goods sold | 4.6 b | 4.4 b | 4.5 b | 5.8 b |
Gross profit | 14.2 b | 15.5 b | 18.4 b | 19.8 b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q1, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.7 b | 4.6 b | 4.9 b | 5 b | 5 b | 5.5 b | 5.9 b | 6 b | 6.5 b | 6.4 b | 6.54 t | 6.9 b | 7.9 b |
Cost of goods sold | 1.1 b | 1.1 b | 1.1 b | 1.1 b | 942 m | 916 m | 1.2 b | 1.4 b | 1.4 b | 1.5 b | 1.62 t | 1.5 b | 1.9 b |
Gross profit | 3.6 b | 3.5 b | 3.8 b | 3.9 b | 4.1 b | 4.6 b | 4.8 b | 4.6 b | 5 b | 4.9 b | 4.92 t | 5.4 b | 6 b |
Gross profit Margin, % | 77% | 76% | 77% | 78% | 81% | 83% | 80% | 77% | 78% | 77% | 75% | 78% | 76% |
- Source: SEC Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 9.6 b | 8.3 b | 8.4 b | 5.1 b |
Accounts Receivable | 3.9 b | 3.7 b | 4.7 b | 4.8 b |
Inventories | 1.2 b | 1.1 b | 1.7 b | 1.4 b |
Current Assets | 17.8 b | 16.1 b | 16.3 b | 16.2 b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q1, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 9 b | 8.1 b | 9.1 b | 7.7 b | 7.9 b | 7.4 b | 9.2 b | 7.6 b | 6.3 b | 6.2 b | 4.7 b | 6.1 b | 9 b |
Accounts Receivable | 3.8 b | 3.7 b | 3.7 b | 3.6 b | 4.2 b | 4.4 b | 4.6 b | 4.8 b | 5 b | 5 b | 4.7 b | 4.9 b | 5.8 b |
Inventories | 1.2 b | 1.1 b | 1 b | 1 b | 1 b | 1.6 b | 1.8 b | 1.8 b | 1.8 b | 1.6 b | 1.4 b | 1.6 b | 1.7 b |
Current Assets | 16.5 b | 17.3 b | 17.8 b | 17.6 b | 15.4 b | 16.9 b | 17.9 b | 16.6 b | 16.8 b | 16.3 b | 15.5 b | 17 b | 20.4 b |
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 4.1 b | 1.8 b | 5.1 b | 6 b |
Inventories | (56 m) | (203 m) | (434 m) | (38 m) |
Accounts Payable | (426 m) | (193 m) | 1.5 b | (1.2 b) |
Cash From Operating Activities | 6.3 b | 3.5 b | 7.5 b | 7 b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q1, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 964 m | 980 m | 1.1 b | 2.6 b | 1 b | 2.4 b | 3.6 b | 1.4 b | 3 b | 4.6 b | 1.7 b | 3.6 b | 2.8 b |
Depreciation and Amortization | 593 m | 158 m | 348 m | 575 m | 268 m | 557 m | 861 m | 374 m | 753 m | 445 m | |||
Inventories | 20 m | (75 m) | (160 m) | (446 m) | 19 m | (160 m) | 28 m | 71 m | 1 m | (71 m) | |||
Accounts Payable | (1 m) | 188 m | 409 m | 1.3 b | 42 m | 89 m | (975 m) | (266 m) | (530 m) | 191 m |
| USD | Y, 2018 |
|---|---|
EV/EBIT | 55.1 x |
Revenue/Employee | 273.6 k |
Financial Leverage | 19.5 x |
AbbVie Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| Stem CentRx (156) | April 28, 2016 | $5.80 b |
Report incorrect company information
AbbVie News and Updates
May 16, 2018
AbbVie bows to pressure to keep cheaper Imbruvica formula on the market
When AbbVie rolled out a single-tablet formulation of its blood cancer drug Imbruvica earlier this year, it pitched the pill to doctors and patients as a convenience. But that convenience came with a hefty price tag—the cost of the smallest dose tripled in price—and that didn't go over well.
May 14, 2018
Hormone Refractory Prostate Cancer Market Significant Profits Estimated to be Generated by 2024
North America will continue to dominate the global Hormone Refractory Prostate Cancer market for due to high prevalence which are diagnosed with advanced technology. Posted via Industry Today. Follow us on Twitter @IndustryToday
May 14, 2018
New Research Report on Retinal Drugs And Biologics Market, 2017-2027
Future Market Insights has announced the addition of the “Retinal Drugs And Biologics Market: Global Industry Analysis and Opportunity Assessment, 2017-2027"report to their offering. Posted via Industry Today. Follow us on Twitter @IndustryToday
May 08, 2018
Gilead: What A Disaster
May 02, 2018
With hepatitis C in freefall, Gilead's bottoming out. The good news? It's bottoming out
Gilead Sciences may have some exciting prospects on the horizon, but for now, its cash-cow hepatitis C business is a big drag. After hep C sales cratered in the first quarter—falling even more than expected—its CFO admitted that the company's bottoming out. The good news? A trough implies growth ahe…
May 01, 2018
AbbVie: Can Mylan Pull Off A Humira Biosimilar?
Report incorrect company information